Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
about
Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysisThe Value of Patient-Centred Registries in Phase IV Drug SurveillanceRisk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims databaseEfficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesTen years with biologics: to whom do data on effectiveness and safety apply?Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Initiation of rheumatoid arthritis treatments and the risk of serious infections.JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.Systematic review of validation studies of the use of administrative data to identify serious infections.Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of RheumatologyNon-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.How well do discharge diagnoses identify hospitalised patients with community-acquired infections?--a validation study.Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analysesRisk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.The risk factors for nosocomial infection in chinese patients with active rheumatoid arthritis in shanghai.Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.Vaccination in patients with chronic rheumatic or autoimmune diseases.Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis."Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".Validity of physician-reported hospitalized infections in a US arthritis registry.Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability.Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritis.Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence.Are biological targets the final goal for rheumatoid arthritis therapy?The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Vaccines and biologics.Adverse reactions to biologic agents and their medical management.Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.Active-comparator design and new-user design in observational studies.Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists.
P2860
Q26786213-2335B741-401D-45EF-8439-3CB30B79B0BAQ29395899-66842AD5-AECD-4ECD-908E-7FFA939DBCAAQ30240183-FC91B170-195B-4438-992C-E02763580BA9Q30717002-308A464F-4931-45FF-BB9E-3E37AB65F79BQ30990764-B3A3DEA5-EBA6-4C96-BDED-B2A283B06EFEQ33578361-8CF7D818-60E1-4732-9F99-94FF74FF1440Q33749195-CDD73B21-465B-402E-B69D-9CA0C8B71633Q33778719-0F4A0CE0-3843-4847-BFF4-CC5A9988E38DQ34019267-5407E043-05DA-4D3D-AB44-0E19E9A620A9Q34276089-C62CE10B-5262-4025-B667-10260DF81B67Q34555474-7A674845-2E74-454F-8838-7038B4E8D385Q34641300-8A0CFA7B-122C-4EA0-ADB5-7FBCB3CCCFC1Q34756501-36A7117E-CE77-4446-A059-5D1E58FF6BACQ35129370-4BAA207C-B9C7-4E9A-BADA-2FB545AE0386Q35572174-74084CAB-02AD-452B-9945-266A4F020DCFQ35617617-99A51AE4-2C75-40F7-8A03-F975E6B11B78Q35617753-8F804D07-FEE3-4678-A3D1-7536C8A932C9Q35636624-CBD0D772-1911-4A2F-8A55-7745207096D0Q35705082-8DF37E7E-4B29-4CF4-B41B-515986080352Q35893575-549857B0-F049-4468-9E74-B2D0A04FEFEAQ35899264-257D8BD2-0397-4989-8FCD-304C5C26391FQ36761926-EF126FC6-BF81-44BA-9E87-072882557043Q36942914-306B813A-ACA2-4B30-B9AF-72B717C1DB5DQ37141193-BE01BF82-A356-4B7D-8246-C7C1AC927B14Q37189376-AAA597EE-0859-48F4-9B46-0AB21CB45674Q37330765-CC2BD95F-F54A-4C01-8E7C-FA02196660BBQ37343166-905E77D4-5871-4AF2-B5F1-98126CBDB2EFQ37347648-D37FBB2A-8754-4B92-A346-461B176303D2Q37632332-4B3F281E-E0BC-4261-8D44-4F054A63F4D0Q37809532-6987F8DD-A33D-4958-9F00-F4F3FA42AA85Q37907921-5722D9D7-64ED-44FE-9AB6-D1402690E83DQ38041208-71FD23DB-6917-4F1C-96B5-818715FFE1D2Q38063474-D0BB91E1-555D-46C6-9C77-3BED6659C64AQ38183297-0E06E6A8-65A1-493E-B3F5-1FBE9ADE8838Q38192553-B27781FF-0ED3-438A-B113-C4BBC58A1294Q38213192-D56F8DFB-C48D-44BA-AB4D-E91D85886B24Q38238948-F780BE2F-F282-4AFD-AA1A-25A05F3645B1Q38306689-856DE862-EE5E-4E29-BFF8-229B9F777191Q38387733-B63B7813-156A-4B0F-A251-46A76B2E7419Q38411930-37158A15-779E-466D-99E3-1F2EDAA01B55
P2860
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
description
scientific article published on 01 April 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2007
@uk
name
Risk of serious bacterial infe ...... necrosis factor α antagonists
@en
Risk of serious bacterial infe ...... necrosis factor α antagonists
@nl
type
label
Risk of serious bacterial infe ...... necrosis factor α antagonists
@en
Risk of serious bacterial infe ...... necrosis factor α antagonists
@nl
prefLabel
Risk of serious bacterial infe ...... necrosis factor α antagonists
@en
Risk of serious bacterial infe ...... necrosis factor α antagonists
@nl
P2093
P921
P356
P1476
Risk of serious bacterial infe ...... rosis factor alpha antagonists
@en
P2093
Aiyuan Xie
Carolyn Martin
Deborah Shatin
Jeffrey R Curtis
Kenneth G Saag
Michael Saag
Nivedita Patkar
P2860
P304
P356
10.1002/ART.22504
P577
2007-04-01T00:00:00Z